Topics

Inhibitory Immune Receptors And Targeted Inflammation Therapy

Chronic Inflammation Cancer Immunotherapy Intercellular Communication & Diseases Multiprotein Complexes and Disease

Inhibitory immune receptors set activation thresholds and prevent protective inflammation from becoming destructive. Many are expressed on myeloid cells, dendritic cells, or lymphocytes and contain immunoreceptor tyrosine-based inhibitory motifs. After ligand binding, these motifs recruit phosphatases such as SHP-1 or SHP-2, which oppose activating kinase cascades. Paired-receptor families illustrate the balance: SIRPalpha transmits inhibitory signals after binding CD47, whereas related SIRP members can activate or regulate adhesion; LILRB receptors also dampen responses to diverse ligands. These systems preserve self-tolerance, limit collateral tissue damage, and help terminate responses. Their effects depend on receptor expression, ligand density, co-engaged activating pathways, and the responding cell type[1][2][3].

The CD47-SIRPalpha axis is a well-defined example. CD47 on host cells delivers a "do-not-eat-me" signal to SIRPalpha-positive phagocytes and restrains engulfment. This protects normal cells but can be exploited by tumors; therapeutic blockade may restore phagocytosis. In inflammatory disease or transplantation, enhancing rather than blocking the interaction could potentially reduce damaging clearance. The same bidirectionality applies to LILRBs: inhibitory signaling can control neutrophil or macrophage activation, yet pathogens may engage these receptors to suppress antimicrobial responses. Expression of activating and inhibitory LILRs in rheumatoid synovium correlates with disease activity in subsets of patients, emphasizing that receptor balance and tissue distribution-not the family name alone-determine biological meaning. CD47-directed agents can affect normal blood cells because CD47 is widely expressed, while checkpoint agonism can impair infection surveillance or tumor immunity. Inhibitory receptors are best viewed as adjustable circuit components whose direction of targeting must match the disease mechanism[1][2][3][4][5].

Targeted therapy can follow two opposite strategies. Antagonists may release an inhibitory checkpoint to strengthen antitumor or antimicrobial immunity; agonists or ligand-targeted antigen delivery may promote tolerance in autoimmunity, allergy, or transplantation. Dendritic-cell receptors are especially attractive for antigen-specific tolerogenic immunotherapy because receptor ligation can combine presentation of a defined antigen with inhibitory costimulation and regulatory cytokines, encouraging regulatory T-cell responses. Antigen structure, carrier, receptor specificity, dendritic-cell subset, and local environment all affect whether tolerance is achieved. A nominally inhibitory receptor can also have activating effects through alternative ligands or adapters, so therapeutic antibodies must be characterized for blocking, agonistic, depleting, and Fc-dependent activities. Safety and patient selection are central. LILRB and SIRP-family homology creates potential cross-reactivity, and species differences complicate preclinical translation. Biomarkers may identify patients whose disease reflects insufficient inhibitory signaling versus those in whom pathogens or tumors exploit excessive restraint. Local or cell-selective delivery, partial rather than complete modulation, and antigen-specific tolerance may widen the therapeutic window[1][2][3][5].

Combination treatment introduces further complexity: releasing one checkpoint while blocking an inflammatory cytokine may produce nonadditive effects on phagocytosis, antigen presentation, and lymphocyte priming. Trials should document receptor and ligand expression in the target tissue, downstream phosphatase engagement, cellular function, and systemic consequences. Dose-escalation studies therefore need mechanistic pharmacodynamic endpoints and careful monitoring for anemia, thrombocytopenia, infection, autoimmunity, and cytokine-related toxicity. Durable tolerance should also be distinguished from transient immunosuppression by testing antigen specificity and persistence after treatment withdrawal. Long-term surveillance will remain necessary. Tissue-selective delivery may improve this balance[1][2][3][5].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L132 Chemokine Compound Library
Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system. The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases. MCE supplies a unique collection of 257 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.

Signaling Pathway Targeting Libraries

83
HY-100388A SHP099 monohydrochloride
SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM.
SHP2   Phosphatase  
Cancer  
76
HY-100388 SHP099
SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth.
SHP2   Phosphatase  
Cancer  
76
HY-16438 RRx-001
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.
CD47   Apoptosis   Parasite  
Digestive System Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Parasitic Infection   Digestive System Inflammation   SARS-CoV-2 Infection  
22
HY-B0183 Ellagic acid
Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
Casein Kinase   Reactive Oxygen Species (ROS)   Endogenous Metabolite   SHP2  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
22
HY-116009 RMC-4550
RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC50 of 0.583 nM.
SHP2   Phosphatase  
Cancer  
11
HY-112368 PHPS1
PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
SHP1   SHP2   Phosphatase  
Cancer   Cardiovascular Disease   Obesity  
7
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-136173 Batoprotafib
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
SHP2   Phosphatase  
Lung Cancer   Prostate Cancer   Pancreatic Cancer  
7
HY-P99029 Magrolimab
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer.

Species: Human

CD47  
HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer  
5
HY-P3970 KRFK
KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-P3970A KRFK TFA
KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach.
TGF-β Receptor  
Inflammation or Immune System Disease  
4
HY-18756 NSC-87877
NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
SHP1   SHP2   Phosphatase   Apoptosis  
Digestive System Disease   Digestive System Inflammation  
3
HY-P990131 Anti-Mouse CD47/IAP Antibody (MIAP301)
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.

Species: Mouse

CD47  
Melanoma   Klebsiella Pneumoniae Infection   Sepsis  
2
HY-15306S Eltrombopag-13C4
Eltrombopag-13C4 (SB-497115-13C4) is 13C-labeled Eltrombopag. Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells.
Thrombopoietin Receptor   Bacterial   Apoptosis  
Cancer   Blood or Cardio-cerebrovascular Disease   Staphylococcus Aureus Infection  
1
HY-P99706 Ligufalimab
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

Species: Human

CD47   Interleukin Related  
Cancer  
1
HY-P99777 Ontorpacept
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
CD47  
Cancer  
1
HY-P99026 Lemzoparlimab
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

Species: Human

CD47  
Cancer  
1
HY-P99533 Urabrelimab
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

Species: Human

CD47   Interleukin Related  
Cancer  
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

Tim3  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer  
1
HY-161952 Sitneprotafib
Sitneprotafib (JAB-3312) is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. Sitneprotafib has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model.
SHP2  
Cancer  
1
HY-P72917 CD47 Protein, Human (HEK293)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293) is the recombinant human-derived CD47 protein, expressed by HEK293 , with tag free.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

1
HY-P700826 SIRP alpha V8/CD172a Protein, Human (Biotinylated, S44L, S50T, I52T, H54R, V57A, HEK293, His-Avi)
SIRP alpha V8/CD172a Protein, Human (Biotinylated, S44L, S50T, I52T, H54R, V57A, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V8/CD172a protein, expressed by HEK293, with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

1
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-W745090 Isomaltulose monohydrate
Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
Formyl Peptide Receptor (FPR)   Akt   ERK   Src   p38 MAPK  
/
HY-P992433 OR502
OR502 is a humanized IgG1 monoclonal antibody targeting LILRB2 (ILT4/CD85d), with a Kd value of 1.18 nM. OR502 binds to LILRB2 with high affinity and blocks its interaction with HLA class I ligands, relieving myeloid cell-mediated immunosuppression, restoring CD8+ T cell function, and reprogramming the immunosuppressive macrophage phenotype, thereby simultaneously enhancing both innate and adaptive antitumor immune responses. OR502 can be used in the research of cancers and advanced cancers (including melanoma, non-small cell lung cancer, sarcoma/soft tissue cancer, and urothelial carcinoma).

Species: Human

LILRB  
Cancer  
/
HY-P3968 Thrombospondin-1 (1016-1021) (human, bovine, mouse)
Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.
CD47  
/
HY-189068 GL-4512
GL-4512 is an orally active LILRB4/ILT3 inhibitor with an IC50 of 37 nM against human targets, and human Kd values of 18.1 nM and 39.2 nM, respectively. GL-4512 directly binds to the extracellular pockets of LILRB4/ILT3 that accommodate their ligands, blocks the LILRB4-SCG2 signaling pathway, and inhibits the downstream SHP1/SHP2 and STAT3 signaling pathways. GL-4512 restores anti-tumor immune activity, promotes the production of IFN-γ and IL-2, enhances the activation of cytotoxic T cells, reduces tumor cell viability, inhibits tumor growth, and strengthens intratumoral immune activation. GL-4512 can be used in research related to colorectal cancer and acute myeloid leukemia.
LILRB   SHP1   SHP2   STAT   IFNAR   Interleukin Related  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma  
/
HY-P11205 Cys-PKHB1
Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-P2194 AtPep3
AtPep3 is a hormone-like peptide. AtPep3 can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings.
Others  
Inflammation or Immune System Disease  
/
HY-P992353 ES009
ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer.

Species: Human

LILRB  
Ovarian Cancer  
/
HY-P11886 GNYTCEVTELTREGETIIELK-N3
GNYTCEVTELTREGETIIELK-N3 (GNYTCEVTELTREGETIIELK-Azide) is a conjugate of an azide (-N3) group and a CD47 functional peptide (GNYTCEVTELTREGETIIELK). Modifying the surface of LNPs with GNYTCEVTELTREGETIIELK significantly reduces the recognition and clearance of LNPs by the mononuclear phagocytic system (MPS) and reduces their accumulation in non-target tissues such as the liver and spleen. The azide group in GNYTCEVTELTREGETIIELK-N3 can undergo click chemistry reactions for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-P991308 TRX385
TRX385 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. TRX385 can be used in anticancer and antiviral research.

Species: Human

LILRB   Transmembrane Glycoprotein  
Cancer   Infection  
/
HY-P991307 BND-35
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model.

Species: Human

LILRB   Transmembrane Glycoprotein  
Cancer  
/
HY-126675G AS2863619 (GMP)
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
CDK   Apoptosis   TGF-beta/Smad   STAT  
Digestive System Disease   Periodontal Disease  
/
HY-P992260 Anti-LILRB3 Antibody
Anti-LILRB3 Antibody is a monoclonal antibody targeting LILRB3/ILT5/CD85a. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB3 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

LILRB  
Inflammation or Immune System Disease  
/
HY-P2194A AtPep3 TFA
AtPep3 TFA is a hormone-like peptide. AtPep3 TFA can enhance salinity tolerance of plants and inhibits the salt-induced bleaching of chlorophyll in seedlings.
Others  
Inflammation or Immune System Disease  
/
HY-187305S [U-15N]-PD-L1
[U-15N]-PD-L1 is the 15N-labeled PD-L1. PD-L1 is expressed on immune cells or aberrantly overexpressed on the surface of various tumor cells; it maintains immune tolerance and acts as a key molecule in tumor immune escape. This isotope can be used in NMR studies to investigate disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Cancer   Inflammation or Immune System Disease  
/
HY-P992388 IO-108
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors.

Species: Human

LILRB  
Cancer  
/
HY-184688 ORS-22
ORS-22 is an immunomodulator with a Kd value of 9.2 nM for human LILRB4. ORS-22 binds directly to the extracellular domain of LILRB4, reverses immunosuppression, restores cytotoxic T cell function, recovers cytokine production, and reduces tumor cell viability. ORS-22 can be used in research related to colorectal cancer and acute myeloid leukemia.
LILRB  
Colorectal Cancer   Acute Myeloid Leukemia  
/
HY-P992259 Anti-LILRB1 Antibody
Anti-LILRB1 Antibody is a monoclonal antibody targeting LILRB1/CD85j/ILT2. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-LILRB1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

LILRB  
Inflammation or Immune System Disease  
/
HY-P10371 PKHB1
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.
Reactive Oxygen Species (ROS)   Thrombopoietin Receptor   Mitochondrial Metabolism   HSP   HSV   CD47  
Inflammation or Immune System Disease   Breast Cancer   Acute Lymphoblastic Leukemia   HSV Infection  
/
HY-P992215 Anti-CD85a/LILRB3 Antibody (7C5)
Anti-CD85a/LILRB3 Antibody (7C5) is a human monoclonal antibody targeting LILRB3/ILT5/CD85a. Anti-CD85a/LILRB3 Antibody (7C5) can be used for research on inflammatory and immune diseases. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).

Species: Human

LILRB  
Inflammation or Immune System Disease  
/
HY-126855S Cholic acid 7-sulfate-d4
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
Isotope-Labeled Compounds   G protein-coupled Bile Acid Receptor 1   MHC  
Metabolic or Endocrine Disease  
/
HY-W713365 Eltrombopag-d3
Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well.
Isotope-Labeled Compounds   Bacterial   Apoptosis   Thrombopoietin Receptor  
Cancer   Infection   Blood or Cardio-cerebrovascular Disease  
/
HY-P991306 ATG-032
ATG-032 is a human monoclonal antibody (mAb) targeting LILRB2/ILT4. ATG-032 can be used in haematological malignancies research.

Species: Human

LILRB   Transmembrane Glycoprotein  
Cancer  
/
HY-P10813 ZLIRTLHEWY
ZLIRTLHEWY is a potent peptide CD47/SIRPα interaction inhibitor. ZLIRTLHEWY is promising for research of cancers.
CD47  
Cancer   Inflammation or Immune System Disease  
/
HY-P990237 Anti-Mouse ICOS Antibody (7E.17G9)
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance T cell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer.

Species: Mouse

CD28  
Cancer   Inflammation or Immune System Disease  
/
HY-P11097 Pep-20
Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer.
CD47  
Breast Cancer   Pancreatic Cancer   Blood Disease  
/
HY-P991727 Zamristobart
Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Human leukocyte immunoglobulin (Ig)-like receptors (LILR)   LILRB  
Cancer   Inflammation or Immune System Disease  
/
HY-P11205A Cys-PKHB1 TFA
Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
CD47   Reactive Oxygen Species (ROS)   Thrombopoietin Receptor  
Inflammation or Immune System Disease  
/
HY-W744699 Larixol
Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
Src   Akt   ERK  
Inflammation or Immune System Disease  
/
HY-P990462 Anti-LILRB4/ILT3/CD85k Antibody
Anti-LILRB4/ILT3/CD85k Antibody is a CHO-expressed humanized antibody that targets LILRB4/ILT3/CD85k. The predicted molecular weight (MW) of Anti-LILRB4/ILT3/CD85k Antibody is 144.36 kDa.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P991023 Safimestomig
Safimestomig (6MW3211) is an CD47/PD-L1-targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer.

Species: Human

CD47   PD-1/PD-L1  
Cancer  
/
HY-P990092 Rolistobart
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic.

Species: Human

LILRB   Transmembrane Glycoprotein  
Cancer  
/
HY-P10420 RS17
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.
CD47   Interleukin Related  
Cancer  
/
HY-P990061 Polzastobart
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

Transmembrane Glycoprotein   LILRB  
Cancer   Inflammation or Immune System Disease  
/
HY-N15135 Arabinoxylan (Medium viscosity)
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome.
Interleukin Related   Toll-like Receptor (TLR)   Fungal   C-type Lectin-like Receptors (CTLRs)  
Glucose Metabolism  
/
HY-P0144 Thrombospondin-1 (1016-1023) (human, bovine, mouse)
Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.
CD47   Apoptosis  
Digestive System Disease   Digestive System Inflammation  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-153740 PF-07284892
PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC50 value of 21 nM. PF-07284892 decreases the expression of pERK.
SHP2  
Cancer  
/
HY-P990858 Anti-CD47 Antibody (B6.H12)
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma.

Species: Human

CD47  
Cancer  
/
HY-P990033 Anzurstobart
Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies.

Species: Human

CD47  
Colorectal Cancer   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-P990132 Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair.

Species: Human/Mouse/Rat

CD47  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-141523 Vociprotafib
Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice.
SHP2   Phosphatase  
/
HY-P72468 SIRP alpha/CD172a Protein, Mouse (HEK293, His)
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane.It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment.SIRP alpha/CD172a Protein, Mouse (HEK293, His) is the recombinant mouse-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P74289 CD47 Protein, Mouse (HEK293, solution)
The CD47 protein, also known as integrin-associated protein (IAP), is an immune checkpoint protein. CD47 binds to membrane integrins and binds ligands platelet reaction-protein-1 (TSP-1) and signal regulatory protein alpha (SIRP伪). CD47 is a potential therapeutic target for some cancers and is also used to treat pulmonary fibrosis. CD47 Protein, Mouse (HEK293, solution) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with tag free.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P70168 LILRB2/CD85d/ILT-4 Protein, Human (HEK293, His)
The LILRB2/CD85d/ILT-4 protein is a receptor for class I MHC antigens and can recognize multiple HLA alleles. It crucially downregulates the immune response and builds tolerance. LILRB2/CD85d/ILT-4 Protein, Human (HEK293, His) is the recombinant human-derived LILRB2/CD85d/ILT-4 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Leukocyte Immunoglobin-like Receptors ILT-4

/
HY-P72517 LILRB5/CD85c/LIR-8 Protein, Human (HEK293, His)
The LILRB5/CD85c/LIR-8 protein functions as a receptor for class I MHC antigens, suggesting a critical role in immune recognition and regulation. Its interaction with MHC class I molecules suggests involvement in surveillance and may influence immune responses. LILRB5/CD85c/LIR-8 Protein, Human (HEK293, His) is the recombinant human-derived LILRB5/CD85c/LIR-8 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Leukocyte Immunoglobin-like Receptors Leukocyte Immunoglobulin Like Receptor B5/LIR-8

/
HY-P75914 LILRB3/CD85a Protein, Human (HEK293, His)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition. Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation. LILRB3/CD85a Protein, Human (HEK293, His) is the recombinant human-derived LILRB3/CD85a protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins NK Cell CD Proteins Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Leukocyte Immunoglobin-like Receptors CD85a/ILT-5

/
HY-P77739 LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc)
The LILRB2/CD85d/ILT-4 protein is a receptor for class I MHC antigens and can recognize multiple HLA alleles. It crucially downregulates the immune response and builds tolerance. LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived LILRB2/CD85d/ILT-4 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Cynomolgus; Source: HEK293

Receptor Proteins Leukocyte Immunoglobin-like Receptors ILT-4

/
HY-P78561 CD47 Protein, Human (Biotinylated, HEK293, mFc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (Biotinylated, HEK293, mFc-Avi) is the recombinant human-derived CD47 protein, expressed by HEK293 , with C-mFc, C-Avi labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78908 CD47 Protein, Human (Biotinylated, HEK293, hFc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (Biotinylated, HEK293, hFc-Avi) is the recombinant human-derived CD47 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P78710 CD47 Protein, Mouse (HEK293, mFc)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Mouse (HEK293, mFc) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P72469 SIRP alpha/CD172a Protein, Cynomolgus (HEK293, His)
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Cynomolgus; Source: HEK293

CD Antigens Receptor Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P77843 SIRP alpha V4/CD172a Protein, Human (HEK293, His-Avi)
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V4/CD172a Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP alpha V4/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and E33G, L44S, T50S, T52I, R54H mutation.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P77844 SIRP alpha V4/CD172a Protein, Human (Biotinylated, HEK293, His-Avi)
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V4/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V4/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and E33G, L44S, T50S, T52I, R54H mutation.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P77846 SIRP alpha V6/CD172a Protein, Human (Biotinylated, HEK293, His-Avi)
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V6/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V6/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and S105P, , , , mutation.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P78639 CD47 Protein, Canine (HEK293, His)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Canine (HEK293, His) is the recombinant canine-derived CD47 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD47 Protein, Canine (HEK293, His) is 122 a.a., with molecular weight of 27-32 kDa.

Species: Canine; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P75912 LILRB3/CD85a Protein, Human (HEK293, Fc)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition. Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation. LILRB3/CD85a Protein, Human (HEK293, Fc) is the recombinant human-derived LILRB3/CD85a protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins NK Cell CD Proteins Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Leukocyte Immunoglobin-like Receptors CD85a/ILT-5

/
HY-P75913 LILRB3/CD85a Protein, Human (Biotinylated, HEK293, His)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition. Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation. LILRB3/CD85a Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived LILRB3/CD85a protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins NK Cell CD Proteins Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Leukocyte Immunoglobin-like Receptors CD85a/ILT-5

/
HY-P77064 LILRB3/CD85a Protein, Mouse (HEK293, His, solution)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition.Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation.LILRB3/CD85a Protein, Mouse (HEK293, His, solution) is the recombinant mouse-derived LILRB3/CD85a protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins NK Cell CD Proteins Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Leukocyte Immunoglobin-like Receptors CD85a/ILT-5

/
HY-P77443 LILRB5/CD85c/LIR-8 Protein, Human (Biotinylated, HEK293, His)
The LILRB5/CD85c/LIR-8 protein functions as a receptor for class I MHC antigens, suggesting a critical role in immune recognition and regulation. Its interaction with MHC class I molecules suggests involvement in surveillance and may influence immune responses. LILRB5/CD85c/LIR-8 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived LILRB5/CD85c/LIR-8 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

Receptor Proteins Biotinylated Proteins Leukocyte Immunoglobin-like Receptors Leukocyte Immunoglobulin Like Receptor B5/LIR-8

/
HY-P78171 LILRB3/CD85a Protein, Human (Biotinylated, HEK293, His-Avi)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition. Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation. LILRB3/CD85a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived LILRB3/CD85a protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins NK Cell CD Proteins Macrophage CD Proteins Monocyte CD Proteins Dendritic Cell CD Proteins Leukocyte Immunoglobin-like Receptors CD85a/ILT-5

/
HY-P78611 CD47 Protein, Rabbit (HEK293, Fc)
The CD47 protein is an adhesive multifunctional protein that coordinates cell-cell interactions, serves as a THBS1 receptor, and regulates integrin signaling through heterotrimeric G proteins. It plays a key role in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cell self-renewal, immune regulation, and memory formation. CD47 Protein, Rabbit (HEK293, Fc) is the recombinant Rabbit-derived CD47 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD47 Protein, Rabbit (HEK293, Fc) is 121 a.a., with molecular weight of 48-58 kDa.

Species: Rabbit; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P704477 CD47 Protein, Human (HEK293, mFc)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293, mFc) is the recombinant human-derived CD47 protein, expressed by HEK293, with C-mFc labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P704478 CD47 Protein, Human (HEK293, His, Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Human (HEK293, His, Avi) is the recombinant human-derived CD47 protein, expressed by HEK293, with C-Avi and C-His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins CD Antigens Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P704884 SIRP alpha V8/CD172a Protein, Human (S44L, S50T, I52T, H54R, V57A, HEK293, His)

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P704886 SIRP alpha V8/CD172a Protein, Human (118a.a, HEK293, Llama Fc)

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P705096 SIRP alpha V8/CD172a Protein, Human (Biotinylated, HEK293, His-Avi)

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P705250 CD47 Protein, Mouse (Biotinylated, HEK293, Fc-Avi)
CD47 is an adhesion protein that regulates integrin signaling through G protein activation and serves as a receptor for thrombospondin THBS1, affecting signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, self-renewal and Immunomodulatory. It regulates pulmonary endothelin EDN1 signaling, acts as a pressor in blood pressure regulation, and is critical for memory formation. CD47 Protein, Mouse (Biotinylated, HEK293, Fc-Avi) is the recombinant mouse-derived CD47 protein, expressed by HEK293 , with C-Avi, C-Fc labeled tag.

Species: Mouse; Source: HEK293

Immune Checkpoint Proteins CD Antigens Biotinylated Proteins Inhibitory Checkpoint Molecules Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Dendritic Cell CD Proteins Epithelial cell CD Proteins Endothelial cell CD Proteins Integrin Associated Protein/CD47

/
HY-P705270 SIRP alpha/CD172a Protein, Mouse (Biotinylated, HEK293, Fc-Avi)
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a, Mouse (Biotinylated, HEK293, Fc-Avi) is the recombinant mouse-derived SIRP alpha/CD172a protein, expressed by HEK293, with N-Avi labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Dendritic Cell CD Proteins Cell Adhesion Molecules (CAMs) SIRP alpha/CD172a Immunoglobulin-like Cell Adhesion Molecules

/
HY-P77064A LILRB3/CD85a Protein, Mouse (HEK293, C-His)
LILRB3/CD85a protein, as a receptor for class I MHC antigens, plays an indispensable role in immune recognition. Activation of LILRB3 occurs through binding to immune receptors such as FCGR2B and B cell receptors, resulting in downregulation of antigen-induced B cell activation. LILRB3/CD85a Protein, Mouse (HEK293, C-His) is the recombinant mouse-derived LILRB3/CD85a, expressed by HEK293, with C-6*His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens NK Cell CD Proteins CD85a/ILT-5

/
HY-P84512 CD47 Antibody (YA4209)
CD47 Antibody (YA4209) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD47.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84679 CD85K Antibody (YA4376)
CD85K Antibody (YA4376) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CD85K. It can be applicated for IHC-P, ICC/IF, FC, ELISA assays, in the background of human.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P80065 CD47 Antibody (YA531)
CD47 Antibody (YA531) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD47.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P88032 CD47 Antibody (YA7717)
CD47 Antibody (YA7717) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD47.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84924 LILRA6 Antibody (YA4621)
LILRA6 Antibody (YA4621) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LILRA6.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81516 LILRB1 Antibody (YA1261)
LILRB1 Antibody (YA1261) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LILRB1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81516A LILRB1 Antibody (YA1261)(PBS only)
LILRB1 Antibody (YA1261) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LILRB1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84512A CD47 Antibody (YA4209)(PBS only)
CD47 Antibody (YA4209) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD47.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84671 LILRB2 Antibody (YA4368)
LILRB2 Antibody (YA4368) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LILRB2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84671A LILRB2 Antibody (YA4368)(PBS only)
LILRB2 Antibody (YA4368) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LILRB2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84679A CD85K Antibody (YA4376)(PBS only)
CD85K Antibody (YA4376) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CD85K. It can be applicated for IHC-P, ICC/IF, FC, ELISA assays, in the background of human.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84680 LILRB1 Antibody (YA4377)
LILRB1 Antibody (YA4377) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LILRB1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84680A LILRB1 Antibody (YA4377)(PBS only)
LILRB1 Antibody (YA4377) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LILRB1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84924A LILRA6 Antibody (YA4621)(PBS only)
LILRA6 Antibody (YA4621) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LILRA6.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/

Keywords

inhibitory immune receptors | SIRPalpha | CD47 | LILRB | immune tolerance | targeted inflammation therapy